The first trial to provide evidence for the treatment of advanced HCC with a PD-1 inhibitor was CheckMate 040 (34), an international multicenter, single-arm, multi-cohort dose escalation and expansion study. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.